Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors.

Anti-CAR antibodies in brain tumor patients are linked to limited durability of chimeric antigen receptor T-cell therapy, undermining the engineered receptor’s persistence.

• Why it matters: Durability has been limited for CAR T-cell treatments in brain tumors, and an antibody response against the engineered receptor is a key suspected barrier.
• What they did: The study tested ways to suppress this antibody attack, using preconditioning drugs or redesigning the chimeric antigen receptor to reduce recognition.
• The result: Suppression of the anti-receptor response helps the CAR T cells and their therapeutic benefit last longer, supporting strategies to improve durability in brain tumors.

AI summary of the abstract · may contain errors · not medical advice · read the paper.